NFE2L2 and hepatocellular carcinoma: In HCC cells, mutations in NFE2L2 or KEAP1 activate the Keap1/Nrf2 pathway, increasing the nuclear abundance of Nrf2 and promoting the subsequent activation of its target genes, which results in tumor cell survival and promotion of tumorigenesis [86].